Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography combined with prostate-specific antigen/free prostate-specific antigen ratio for bone metastasis of prostate cancer

doi:10.12998/wjcc.v12.i20.4082

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1149)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

HTML

571

Figures (1-4)

127

Tables (1-2)

137

Sum=866

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

219

Sum=247

Jul 16, 2024 (publication date) through Jan 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Jul 16, 2024; 12(20): 4082-4090
Published online Jul 16, 2024. doi: 10.12998/wjcc.v12.i20.4082

Open in New Tab Full Size Figure Download Figure

Figure 1 Diagnosis efficacy of technetium-99m-methylene diphosphonate single photon emission computed tomography (SPECT)/computed tomography (CT) and SPECT/CT in diagnosing prostate cancer bone metastasis. ^aP < 0.05. 99mTc-MDP SPECT/CT: Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography.

Open in New Tab Full Size Figure Download Figure

Figure 2 Comparison of prostate-specific antigen (PSA)/free prostate-specific antigen (PSA) values of patients with and without prostate cancer bone metastasis in the control and experimental groups. ^aP < 0.05, ^bP < 0.05 between patients with prostate cancer bone metastasis (PCBM) and without PC and between patients with PCBM and with PC only, respectively. CE: Exp group; CG: Ctrl group.

Open in New Tab Full Size Figure Download Figure

Figure 3 Specificity and sensitivity of technetium-99m-methylene diphosphonate single photon emission computed tomography (SPECT)/computed tomography (CT) imaging combined with prostate-specific antigen (PSA)/free PSA in diagnosing prostate cancer bone metastasis. 99mTc-MDP SPECT/CT: Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography.

Open in New Tab Full Size Figure Download Figure

Figure 4 Accuracy of technetium-99m-methylene diphosphonate single photon emission computed tomography (SPECT)/computed tomography (CT) imaging combined with serum prostate-specific antigen (PSA)/free PSA ratio to prostate cancer bone metastasis. 99mTc-MDP SPECT/CT: Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography.

Citation: He J, Zhong YP, Zhang S. Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography combined with prostate-specific antigen/free prostate-specific antigen ratio for bone metastasis of prostate cancer. World J Clin Cases 2024; 12(20): 4082-4090
URL: https://www.wjgnet.com/2307-8960/full/v12/i20/4082.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i20.4082